

## 17 参考文献

- Aiba K, Horikoshi N, Sasaki Y, et al. A phase II study of paclitaxel (BMS-181339) by 24 hours infusion in patients with advanced or metastatic breast cancer. *J. New Remedies. Clinics.* 46:467-475, 1997.
- Aisner J and Abrams JS. The treatment of metastatic breast cancer. *In Breast cancer controversies in management.* Wise L and Johnson H eds, Futura Publishing Company, Inc., pp459-478, 1994.
- Antman K, Ayash L, Elia A, et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. *J. Clin. Oncol.* 10:102-110, 1992.
- Bronchud MH, Howell A, Crowther D, Hopwood P, Souza LM, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. *Br. J. Cancer* 60:121-125, 1989.
- Carmo-Pereira J, Costa FO, Henriques E, et al. A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. *Br. J. Cancer* 56:471-473, 1987.
- Chaudhary PM and Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic cells. *Cell* 66:85-94, 1991.
- Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the *mdr1* (P-glycoprotein) gene from multidrug-resistant human cells. *Cell* 47:381-389, 1986.
- Choi K, Chen C, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the *mdr1* (P-glycoprotein) gene. *Cell* 53:519-529, 1988.
- Choi K, Frommel TO, Stern RK, Perez CF, Kriegler M, Tsuruo T, Roninson IB. Multidrug resistance after retroviral transfer of the human *MDR1* gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. *Proc. Natl. Acad. Sci. USA* 88:7386-7390, 1991.
- Cowan, K. H., Moscow, J. A., Huang, H., Zujewski, J. A., O'Shaughnessy, J., Sorrentino, B., Hines, K., Carter, C., Schneider, E., Cusack, G., Noone, M., Dunbar, C., Steinberg, S., Wilson, W., Goldspiel, B., Read, E. J., Leitman, S. F., McDonagh, K., Chow, C., Abati, A., Chiang, Y., Chang, Y. N., Gottesman, M. M., Pastan, I., and Nienhuis, A.: Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. *Clin. Cancer Res.* 5: 1619-1628, 1999.

- Crown J and Norton L. Potential Strategies for Improving the Results of High-dose Chemotherapy in patients with metastatic Breast Cancer. *Ann. Oncol.* 6(Suppl 4): s21-s26, 1995.
- Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. *Hum. Gene Ther.* 7: 401-416, 1996.
- Deisseroth AB, Holmea F, Hortobagyi G, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: A pilot trial. *Hum. Gene Ther.* 5: 1507-1522, 1994
- Douer D, Chaiwun B, Glaspy J, Watkins K, Vesico R, Cote R. Analysis of peripheral blood progenitor cell harvests for occult breast cancer micrometastasis using a sensitive immunohistochemical method. *Proc. Am. Soc. Clin. Oncol.* 12:62(#51), 1993.
- Dunphy F, Spitzer G, Rossiter-Fornoff JE, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. *Cancer* 73:2157-2167, 1994.
- Ebbs SR, Saunders JA, Graham H, A'Hern RPA, Bates T, Baum M. Advanced breast cancer. A randomised trial of epirubicin at two different dosages and two administration systems. *Acta Oncol.* 28:887-892, 1989.
- Galski H, Sullivan M, Willingham MC, Chin K-V, Gottesman MM, Pastan I, Merlino GT. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia. *Mol. Cell. Biol.* 9:4357-4363, 1989.
- Gottesman MM and Pastan I. The multidrug resistance (MDR1) gene as a selectable marker in gene therapy. *Human Gene Transfer* 219:185-191, 1991.
- Gottesman MM, Ambudkar SV, Ni B, Aran JM, Sugimoto Y, Cardarelli CO, Pastan I. Exploiting multidrug resistance to treat cancer. *Cold Spring Harbor Symposia on Quantitative Biology* 59:677-683, 1994a.
- Gottesman MM, Germann UA, Aksenitjevich I, Sugimoto Y, Cardarelli CO, Pastan I. Gene transfer of drug resistance genes. Implications for cancer therapy. *Annals New York Acad. Sciences* 716:126-139, 1994b.
- Gottesman MM, Hrycyna C, Schoenlein PV, Germann UA, and Pastan I. Genetic analysis of the multidrug transporter. *Annu. Rev. Genetics* 29: 607-649, 1995.
- Guild BC, Mulligan RC, Gros P, Housman DE. Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. *Proc. Natl. Acad. Sci. USA* 85:1595-1599, 1988.

Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. *Cancer Gene Ther.* 1:21-25, 1994.

Harris JR, Morrow M and Bonadonna G. *Cancer of the Breast Cancer: Principles and Practice of Oncology.* DeVita VT, Hellmans and Rosenberg SA eds, JB Lippincott Co., pp1264-1332, 1993.

Hesdorffer, C., Ayello, J., Ward, M., Kaubisch, A., Vahdat, L., Balmaceda, C., Garrett, T., Fetell, M., Reiss, R., Bank, A., and Antman, K.: Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. *J. Clin. Oncol.* 16: 165-172, 1998.

Hesdorfer C, Antman K, Bank A, Fetell M, Mears G, and Begg M. Human MDR gene transfer in patients with advanced cancer. *Hum. Gene Ther.* 5:1151-1160, 1994.

Hesdorfer C, Ayello J, Ward M, Reiss R, Vahdat L, Fetell M, Garrett TD, Bank A, Antman K. A phase I clinical trial using MDR-transduced marrow and/or peripheral blood CD34+ cells. *Proc. Am. Soci. Clin. Oncol.* 16: 88a, 1997.

Hesdorfer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Resii R, Bank A, and Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. *J. Clin. Oncol.* 16:165-172, 1988

Hibino, H., Tani, K., Ikebuchi, K., Wu, M., Sugiyama, H., Nakazaki, Y., Tanabe, T., Takahashi, S., Tojo, A., Suzuki, S., Tanioka, Y., Sugimoto, Y., Nakahata, T., and Asano, S.: The common marmosetts as a target preclinical primate model for cytokine and gene therapy studies. *Blood* 93: 2839-2848, 1999.

Hortobagyi GN, Frye DU, Buzdar AU et al. Complete remissions in metastatic breast cancer: A thirteen year report. *Proc Am Soc Clin Oncol* 7:37(#143), 1988.

Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. *J Clin Oncol* 2:1281-1288, 1984

Inoue, K., Ogawa, M., Horikoshi, N., Aiba, K., Mukaiyama, T., Mizunuma, N., Itami, S., Hirano, A., Matsuoka, A., and Mataumura, T.: Evaluation of prognostic factors for 233 patients with recurrent breast cancer. *Jpn. J. Clin. Oncol.* 21: 334-339, 1991.

Inoue K, Ogawa M, Inagaki J, et al. A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. *Jpn. J. Cancer Chemother.* 11 : PART-I, 1832-1837, 1984.

- Ito, Y., Mukaiyama, T., Ogawa, M., Mizunuma, N., Takahashi, S., Aiba, K., and Horikoshi, N.: Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up. *Cancer Chemother. Pharmacol.* 43: 8-12, 1999.
- Ito Y, Horikoshi N, Watanabe T, et al. A phase II study of paclitaxel (BMS-181339) by 3 hours infusion in patients with advanced or metastatic breast cancer. *J. New Remedies. Clinics.* 46:476-486, 1997.
- Jones RB, Shpall EJ, Ross N et al. AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support for advanced breast cancer. Current results. *Proc. Am. Soc. Clin. Oncol.* 9:9(#30), 1990.
- Kaufman D and Chabner BA. Clinical strategies for cancer treatment: The role of drugs. *In* *Cancer chemotherapy and biotherapy.* Chabner BA and Longo DL eds, Lippincott-Raven Publishers pp1-16, 1996.
- Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K. P-glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly<sup>185</sup> with an altered pattern of multidrug resistance. *Biochem. Biophys. Res. Commun.* 162:224-231, 1989.
- Lincke CR, van der Blik AM, Schuurhuis GJ, van der Velde-Koerts T, Smit JJM, Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human *mdr1* complementary DNA. *Cancer Res.* 50:1779-1785, 1990.
- Mansi JL, Berger U, McDonnell T, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. *J. Clin. Oncol.* 7:445-449, 1989.
- McLachlin JR, Eglitis MA, Ueda K, Kantoff PW, Pastan IH, Anderson WF, Gottesman MM. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. *J. Natl. Cancer Inst.* 82:1260-1263, 1990.
- Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pasta I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. *Proc. Natl. Acad. Sci. USA* 88:547-551, 1991a.
- Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: Efficacy, potency, and toxicity. *Cancer Res.* 51:5417-5424, 1991b.
- Miller AD, and Buttimore C. Redesign of retrovirus packaging cell line to avoid recombination leading to helper virus production. *Mol. Cell. Biol.* 6: 2895-2902, 1986.
- Moscow, J. A., Huang, H., Carter, C., Hines, K., Zujewski, J., Cusack, G., Chow, C., Venzon, D., Sorrentino, B., Chiang, Y., Goldspiel, B., Leitman, S., Read, E. J., Abati, A., Gottesman,

M. M., Pastan, I., Sellers, S., Dunbar, C., and K. H. Cowan.: Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. *Blood* 94: 52-61, 1999.

Moscow J, Zujewski J, Huang H, Sorrentino B, Chiang Y, Wilson W, Cullen E, McAtee N, Gottesman M, Pastan I, Dunber C, Nienhuis A, Cowan K. Hematopoietic reconstitution with CD34-selected cells transduced with a retroviral vector containing the *MDR1* gene in patients with metastatic breast cancer. *Proc. Am. Assoc. Cancer Res.* 38: 343, 1997.

Mukaiyama T, Ogawa M, Horikoshi N, et al. A randomized trial comparing ACF (adriamycin, cyclophosphamide, fltorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, fltorafur) An non-cross resistant alternating chemotherapy in recurrent and advanced breast cancer. *Jpn. J. Cancer Chemother.* 16: PART-I, 327-332, 1989.

Murosaki S, Inagaki J, Horikoshi N, et al. ACF combination consisting of adriamycin, cyclophosphamide and oral fltorafur for recurrent advanced breast cancer. *J. Jpn. Soc. Cancer Ther.* 16:8-14; 1981.

Okochi E, Iwahashi T, Ariyoshi K, Watabe H, Tsuruo T, Ono K. Establishment and evaluation of MRK16 magnetic cell sorting assays for detecting low expression of multidrug resistance P-glycoprotein using human leukemia cell lines and peripheral blood cells from healthy donors. *J. Immunol. Methods* 187:127-137, 1995.

O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox, M, Leitman S, Gottesman MM, Pastan I, Denicoff RN, Noone M, and Gress R. Retroviral mediated Transfer of the human multidrug resistance gene (*MDR-1*) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. *Hum. Gene Ther.* 5: 891-911, 1994.

Ostrove JM. Safety testing programs for gene therapy viral vectors. *Cancer Gene Ther.* 1:125-131, 1994.

Rahman, Z. U., Hortobagyi, G. N., Buzdar, A. U., and Champlin, R.: High-dose chemotherapy with autologous stem cell support in patients with breast cancer. *Cancer Treatment Reviews.* 24: 249-263, 1998.

Rahman, Z., Kavanagh, J., Champlin, R., et al., Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. *Clin. Cancer Res.* 4: 2717-2721, 1998.

Pastan I, Gottesman MM, Ueda K, Lovelace E, Rotherford AV, Willingham MC. A retrovirus carrying an *MDR1* cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. *Proc. Natl. Acad. Sci. USA* 85:4486-4490, 1988.

Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. *J. Clin. Oncol.* 6:1368-

1376, 1988.

Podda S, Ward M, Himmelstein A, Richardson C, De La Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A. Transfer and expression of the human multiple drug resistance gene into live mice. *Proc. Natl. Acad. Sci. USA* 89:9676-9680, 1992.

Ross AA, Cooper BW, Lazarus HM, et al. Incidence of tumor cell contamination in peripheral blood stem cell collections from breast cancer patients. *Proc. Am. Soc. Clin. Oncol.* 12:69(#77), 1993.

Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185--Val-185 substitution in P-glycoprotein. *Proc. Natl. Acad. Sci. USA* 87:7225-7229, 1990.

Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human *MDR1*. *Science* 257:99-103, 1992.

Sugimoto Y, Aksentjevich I, Gottesman MM, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. *Bio/Technology* 12:694-698, 1994.

Sugimoto Y, Hrycyna CA, Aksentjevich I, Pastan I, Gottesman MM. Coexpression of a multidrug-resistance gene (*MDR1*) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of *MDR1*-transduced cells. *Clin. Cancer Res.* 447:447-457, 1995a.

Sugimoto Y, Aksentjevich I, Murray GJ, Brady RO, Pastan I, Gottesman MM. Retroviral coexpression of a multidrug resistance gene (*MDR1*) and human  $\alpha$ -galactosidase A for gene therapy of Fabry disease. *Hum. Gene Ther.* 6:905-915, 1995b.

Sugimoto Y, Tsuruo T, Pastan I, and Gottesman MM. Application of the *MDR1* gene for human gene therapy. *In* *Multidrug Resistance in Cancer Cells*. Gupta S and Tsuruo T eds, John Wiley & Sons, Ltd., 435-449, 1996a

Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM, and Tsuruo T. Coexpression of a multidrug-resistance gene (*MDR1*) and herpes simplex virus thymidine kinase gene in a bicistronic retrovirus vector Ha-MDR-IRES-TK allows selective killing of *MDR1*-transduced human tumors transplanted in nude mice. *Cancer Gene Ther.* in press, 1996b

Taguchi T, Hirata K, Kunii Y, et al. An early phase II clinical study of RP56976 (Docetaxel) in patients with breast cancer. *Jpn. J. Cancer Chemother.* 21:2453-2460, 1994a.

Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP 56976 (Docetaxel) in patients with advanced/recurrent breast cancer. *Jpn. J. Cancer Chemother.* 21:2625-2632, 1994b.

Tannock IF, Boyd NF, Deboer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. *J Clin Oncol* 6:1377-1387, 1988.

Tormey DC, Gelman R, Band PR, et al. Comparison of induction chemotherapies for metastatic breast cancer: An Eastern Cooperative Oncology Group Trial. *Cancer* 50:1235-1244, 1982.

Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug-resistance (*mdr1*) gene: cDNA cloning and transcription initiation. *J. Biol. Chem.* 262:505-508, 1987a.

Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. *Proc. Natl. Acad. Sci. USA* 84:3004-3008, 1987b.

Ward M, Richardson C, Pioli P, Smith L, Podda S, Goff S, Hesdorffer C, Bank A. Transfer and expression of the human multiple drug resistance gene in human CD34<sup>+</sup> cells. *Blood* 84:1408-1414, 1994.

死因の概要。厚生指標 国民衛生の動向 44 : 53-55, 1997.

部位別悪性新生物 死亡数の年次推移。厚生指標 国民衛生の動向 44 : 433-434, 1997.

杉本芳一。個体で機能する薬剤選択マーカー導入による遺伝子治療の効率化。蛋白質核酸酵素 40:2635-2644, 1995.